|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our results indicate a remarkable application of R72P genotyping in the clinical setting: refine patient subclassification to identify those with an adverse clinical course despite tumour free lymph node status.
|
29286914 |
2018 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Tissue culture and mouse model studies show that the presence of the arginine (R) or proline (P) coding single nucleotide polymorphism (SNP) of the tumor suppressor gene p53 at codon 72 (p53 R72P) differentially affects the responses to genotoxic insult.
|
28594296 |
2017 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Several previous studies evaluated the association between the Arg72Pro (rs1042522) polymorphism in the TP53 tumor suppressor gene and colorectal cancer (CRC).However, the results are conflicting.
|
27901479 |
2017 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
ERCC1 Lys259Thr (rs735482), ERCC2 Lys751Gln (rs13181), ERCC5 His46His C>T (rs1047768), XRCC1 Arg399Gln (rs25487), TP53 Arg72Pro (rs1042522) and MDM2 309T>G (rs2279744) were analyzed on tumor DNA.
|
28351583 |
2017 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Genetic data revealed that the p53 Arg72Pro genotype was found to be greatly associated with breast cancer risk (p<0.001), as well as tumor site (p=0.046).
|
25750340 |
2015 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
We here studied the association of rs1219648 in FGFR2 and rs1042522 in TP53 and their interaction in development of early onset sporadic breast cancer in Iranian Azeri population to evaluate epistatic effects on the risk of mammary neoplasia.
|
25292094 |
2014 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Studies on the association of a polymorphism in codon 72 of the p53 tumour suppressor gene (rs1042522) with cervical neoplasia have inconsistent results.
|
23441193 |
2013 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The aim of this study was to detect TP53 Arg72Pro polymorphism in postmenopausal patients with endometrial cancer (EC), to evaluate the risk of EC connected with it, as well to check for possible relationships with staging, grading and some risk factors of this neoplasm.
|
24379271 |
2013 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The HPV E6 oncoprotein binds to the tumor suppressor gene product p53, promoting its degradation; the Arg allele of p53 Arg72Pro polymorphism binds more ardently with HPV E6 than the Pro variant.
|
23065429 |
2012 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The Arg72Pro genotype has no significant effects in patients with TP53 mutated tumors, in which p53 is non-functional.
|
23071787 |
2012 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Single nucleotide polymorphisms (SNP) in codon Arg72Pro of P53 results in impairment of the tumor suppressor activity of the gene.
|
23167335 |
2012 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
In recent years, a new physiological role in human fertility regulation has emerged for the tumor- suppressor p53 gene (P53), and the P53 Arg72Pro polymorphism has been associated with recurrent implantation failure in humans.
|
22532853 |
2012 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The analyses indicate that MDM2 SNP309 serves as a tumor susceptibility marker, and that there is an association between MDM2 SNP309 and p53 Arg72Pro regarding tumor susceptibility.
|
21619694 |
2011 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
To investigate the possible association between the codon 72 polymorphism (Pro72Arg, rs1042522) of the tumor suppressor gene (TP53) and the presence of coronary artery disease (CAD) in Chilean subjects.
|
21252575 |
2011 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
In addition, we showed that BC patients with rs1042522 CC genotype were characterized by only unifocal tumors and decreased frequency of lymph node metastases (p=0.03).
|
21810023 |
2011 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Results indicated that Arg72Pro is associated with higher susceptibility to cancer in some tumor sites, mainly hepatocarcinoma.
|
20886596 |
2011 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
There was no evidence of such an effect on survival within the TP53-mutated tumor group for TP53 R72P carriers but a suggestion of an effect for MDM2 SNP309 carriers (GG vs. TT-genotype HR 2.99, P = 0.06).
|
21667122 |
2011 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
MDM2 SNP309 and p53 Arg72Pro in cutaneous melanoma: association between SNP309 GG genotype and tumor Breslow thickness.
|
20535124 |
2010 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this hospital-based case-control study, four potentially functional single-nucleotide polymorphisms -1628 G>A (rs1591420), -606 T>C [rs4978620, in complete linkage disequilibrium with -249T>C (rs2012775) and -122 G>A(rs2012566)], c.179 C>T p.Ala60Val (rs2269700) and 3' untranslated region-rs3750505 as well as the TP53 tumor suppressor gene codon 72 (Arg72Pro, rs1042522) polymorphism were genotyped in 1111 non-Hispanic Whites SCCHN patients and 1130 age-and sex-matched cancer-free controls.
|
20935061 |
2010 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Furthermore, we also found that the TP53 R72P polymorphism was not linked to tumor histologic type, histologic grade, lymph node metastases, and tumor size.
|
20193851 |
2010 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The germ-line polymorphisms TP53 Arg72Pro and MDM2 SNP309 T>G are risk factors for tumor development and affect response to chemotherapy and survival in several cancers, but their prognostic and predictive value in patients with high-grade osteosarcomas is not yet defined.
|
19451596 |
2009 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
There have been inconsistent reports regarding increased risk of POAG and a polymorphism (Arg72Pro) within the tumor suppressor gene, p53.
|
19784392 |
2009 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
Patients who had the allele Pro of the TP53 Arg72Pro polymorphism had an increased risk of tumor development (odds ratio, OR = 3.23; confidence interval at 95%, 95%CI = 1.71-6.08; P = 0.003), as did the allele Ser of TP53 Pro47Ser polymorphism (OR = 1.28; 95%CI = 0.03-2.10; P = 0.01).
|
19224462 |
2009 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
The polymorphism rs1042522 at codon 72 of the TP53 tumour-suppressor gene has been investigated as a genetic cofactor.
|
19625214 |
2009 |
|
Neoplasms
|
|
0.100 |
GeneticVariation
|
BEFREE |
To evaluate the significance of the TP53 mutation as a molecular marker to predict the prognosis of CRC patients, especially those who received postoperative chemotherapy, we examined the mutation by direct sequencing from fresh CRC tumors and evaluated the R72P polymorphism of the mutated TP53 by a combined mutant allele- and polymorphic allele-specific polymerase chain reaction (PCR).
|
19954513 |
2009 |